| Community Cancer Center -- Let's grab opportunity
I had been out of the nest for several years before my mother was diagnosed with Lymphoma. It started as a small lump on the side of her neck and then masses were found throughout her body. The diagnosis was not good and, with aggressive treatments, the doctors predicted a life expectancy of two to five years. Obviously, the news stunned our family. My mother was a very strong-willed woman, but how could she possibly fight this angry invader? I can only imagine how difficult this would be to deal with if I had been a child still needing a mother to direct my life. I recall the day my best friend's mother died from bone cancer when he was just 16 years of age. The trauma he experienced probably played a role in the direction his life took, which was not the path many of us would willingly choose.
Drug Combination Slows Progression Of Treatment Resistant Bone ...
Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells, according to a clinical trial led by a University of North Carolina at Chapel Hill School of Medicine researcher.
The phase III trial included 646 patients from 18 countries with relapsed or refractory multiple myeloma, a condition in which cancerous cells continue to multiply despite treatment. Patients in the trial were randomly assigned to receive the drug bortezomib (Velcade), standard therapy for relapsed multiple myeloma, or a combination of Velcade and Doxil, a chemotherapy drug (doxorubicin) delivered via liposomes, or microscopic fat bubbles.
An interim analysis of study participants who received the combination treatment showed a better response in the combination group than in participants who received standard treatment.
Crawford child gives back to Memphis hospital helping him
In August 2005, 8-year-old Brandon Thomas of Crawford was doing what any boy his age would - horseplaying as rough-and-tumble as the best of them.But when horseplay led to a pain in his leg, his family took him to a doctor at Baptist Memorial Hospital-Golden Triangle in Columbus.“We thought his leg was broken or injured," remembered Brandon's father, Jimmy Thomas.Brandon was diagnosed with osteosarcoma, the most common form of bone cancer, found mostly in males and characterized by a pain in the leg or knee.Since then, Brandon has been in and out of the St. Jude Children's Research Hospital in Memphis for treatment and chemotherapy. .
Data Show Geron's Telomerase Inhibitor Cancer Drug is Active ...
Geron Corporation (Nasdaq:GERN) today announced that its telomerase inhibitor cancer drug, GRN163L, is active against cancer stem cells from multiple myeloma patients, according to data presented at the American Society of Hematology 48th Annual Meeting in Orlando, Fla. Resulting from a collaboration between Geron and investigators with the department of oncology at the Johns Hopkins University School of Medicine, the data demonstrated activity in a model derived from multiple cell lines as well as cells from fresh specimens taken from the bone marrow of multiple myeloma patients. Cancer stem cells, which are often resistant to standard treatments, are believed to be critically important to cancer's ability to replicate and spread throughout the body. Johns Hopkins' William Matusi, M.D., was the lead author of the study, which Richard J.
Trial shows bortezomib and lenalidomide are better therapy together
(HealthDay News) - A combination of two drugs - bortezomib and lenalidomide - designed to treat the bone marrow cancer multiple myeloma may be more effective together than when the drugs are used individually, a U.S. study concludes. The phase I clinical trial, led by researchers at the Dana-Farber Cancer Institute in Boston, included 38 patients whose cancer had recurred after previous treatment and continued to progress despite other therapies. The patients were divided into groups that received successively higher doses of bortezomib (brand name Velcade) and lenalidomide (brand name Revlimid). Some of the patients also received a standard myeloma medication called dexamethasone, which adds to the effects of both bortezomib and lenalidomide. Of the 36 patients who could be evaluated at the end of the trial, 58 percent had responded to the combined treatment, including six percent who had complete remission.
CSU, Mayo Clinic team up to treat cancer
A new partnership between Colorado State University and one of the worlds premiere cancer research and treatment centers could help new treatments get to patients faster.
CSU and the Mayo Clinic today signed a multiyear collaborative research agreement aimed at developing treatments for cancer and infectious disease patients, according to a press release from the university.
The Animal Cancer Center, housed at CSUs Veterinary Teaching Hospital, has been conducting research on treating animal cancer patients that can directly translate to treating human cancer patients, including implants for bone cancer patients who would otherwise have to undergo limb amputation and a radiation delivery process that allows greater targeting and higher treatment levels while cutting the side effects of radiation treatment.
Kennedy`s Story: Fighting Cancer, Again
These scrapbooks contain the life story of 12-year-old Kennedy Bruce. Her life story is unique. For the second time in her short life, Kennedy is fighting cancer.
"In 1998, she was diagnosed with neuroblastoma cancer," remembers Kennedy`s mom, Nicole.
Kennedy went through chemotherapy, radiation, and a bone marrow transplant. And for nearly six years, she was cancer-free. But on March 28th, 2006, another devastating diagnosis. Kennedy was diagnosed with osteosarcoma.
"It`s a common bone cancer among children. Hers is actually caused by radiation treatment she had when she was little," explains her mother.
Kennedy did eight of 20 rounds of chemo. But complications, including heart and kidney failure, forced her to stop.
"We didn`t do a lot of the chemo, but we also know there are miracles and she can get a miracle again.
World's Largest Clinical Trial Into Rare Bone Cancer 'well ...
The world's largest study aimed at improving the treatment of a rare type of bone cancer that mainly affects children and young adults is well underway, an international conference was told.
The EURAMOS clinical trial, which involves a collaboration across 11 European countries, as well as the US and Canada, is on course to recruit some 1400 patients over the next few years to improve treatment for osteosarcoma, the most common bone cancer in children.
Doctors and scientists meeting at a conference in Stuttgart, Germany last week heard that recruitment for the trial was on track, with some 335 patients so far being treated within the trial.
The conference, - Pan European Sarcoma Trials - moving forward in a climate of increasing economic and regulatory pressure', represented a unique gathering of experts in the field of the type of cancer called sarcomas.
|
